Evidence map›Paper›PMID 19039293›Full record

ArticleCancer biology & therapy2008

Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells.

Shayna L Showalter, Yu-Hung Huang, Agneszka Witkiewicz, Christina L Costantino, Charles J Yeo, Jordan J Green, Robert Langer, Daniel G Anderson, Janet A Sawicki, Jonathan R Brody

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. New targeted therapies in pancreatic cancer.World journal of gastroenterology · 2015
    Review
  11. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2014
    Article
  12. Article
  13. Article
  14. Gene delivery nanoparticles specific for human microvasculature and macrovasculature.Nanomedicine : nanotechnology, biology, and medicine · 2012
    Article
  15. Article
  16. Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2012
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shayna L ShowalterDepartment of Surgery, Thomas Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Yu-Hung Huang
Agneszka Witkiewicz
Christina L Costantino
Charles J Yeo
Jordan J Green
Robert Langer
Daniel G Anderson
Janet A Sawicki
Jonathan R Brody
Massachusetts Institute of Technology · USThomas Jefferson University · USLankenau Institute for Medical Research · US

Funding

CONTROLLED RELEASE OF MACROMOLECULESR01EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL, TRAVERSO, CARLO GIOVANNI · 2002 to 2021
$6.1M
Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
Targeted Nanoparticle DNA Therapy for Ovarian CancerR01CA132091 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI SAWICKI, JANET A · 2008 to 2012
$1.4M
NCI NIH HHS R01 CA132091NIBIB NIH HHS EB00244NIBIB NIH HHS R01 EB000244NIBIB NIH HHS R37 EB000244
6 · The paper itself

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related deaths in this country, and there is currently no effective targeted treatment for this deadly disease. A dire need exists to rapidly translate our molecular understanding of this devastating disease into effective, novel therapeutic options. Mesothelin is a candidate target protein shown by a number of laboratories to be specifically overexpressed in pancreatic cancers and not in the adjacent normal tissue. Translational investigations have shown promising results using this molecule as a therapeutic target (e.g., vaccine strategies). In addition, the mesothelin promoter has been cloned and dissected and can therefore be used as a vehicle for regulating expression of DNA sequences. Using a novel, proven, biodegradable nanoparticulate system, we sought to target mesothelin-expressing pancreatic cancer cells with a potent suicide gene, diphtheria toxin-A (DT-A). We first confirmed reports that a majority of pancreatic cancer cell lines and resected pancreatic ductal adenocarcinoma specimens overexpressed mesothelin at the mRNA and protein levels. High mesothelin-expressing pancreatic cancer cell lines produced more luciferase than cell lines with undetectable mesothelin expression when transfected with a luciferase sequence under the regulation of the mesothelin promoter. We achieved dramatic inhibition of protein translation (>95%) in mesothelin-expressing pancreatic cancer cell lines when DT-A DNA, driven by the mesothelin promoter, was delivered to pancreatic cancer cells. We show that this inhibition effectively targets the death of pancreatic cancer cells that overexpress mesothelin. The work presented here provides evidence that this strategy will work in pre-clinical mouse pancreatic cancer models, and suggests that such a strategy will work in the clinical setting against the majority of pancreatic tumors, most of which overexpress mesothelin.

Indexed as

Drug Delivery SystemsGene Expression Regulation, NeoplasticAdenocarcinomaCell Line, TumorDiphtheria ToxinGene Expression ProfilingGPI-Linked ProteinsHumansImmunohistochemistryMembrane GlycoproteinsMesothelinModels, BiologicalNanoparticlesPancreatic NeoplasmsPromoter Regions, GeneticRNA, MessengerDiphtheria ToxinGPI-Linked ProteinsMembrane GlycoproteinsMesothelinMsln protein, mouseRNA, Messenger

Identifiers

PMID19039293
PMCPMC3218426
OpenAlexW1988345537

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.